Nitroglycerin for Liver Cancer

This trial aims to explore whether nitroglycerin, commonly used for heart conditions, can improve blood flow in liver cancer (hepatocellular carcinoma) patients during transarterial chemoembolization (TACE). Researchers will use a special imaging technique to observe changes in blood flow caused by nitroglycerin. Patients with specific, untreated liver tumors suitable for TACE may qualify for this study. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Research has shown that nitroglycerin is generally well-tolerated in treating liver cancer. One study found that patients who received doses of 200-300 micrograms, similar to those planned for this trial, experienced increased blood flow to their tumors in 77% of cases, indicating potential treatment efficacy. The study reported no serious side effects, suggesting nitroglycerin's safety in this context. Additionally, nitroglycerin's use in other medical treatments provides some confidence in its safety. However, as this is a Phase 2 trial, further research is necessary to fully confirm its safety.¹²³⁴⁵

Unlike the standard treatments for liver cancer, which often focus on directly targeting tumors with chemotherapy or radiation, nitroglycerin works differently. It acts by enhancing blood flow to the liver, potentially improving the delivery and effectiveness of other treatments like transarterial chemoembolization (TACE). Researchers are excited about nitroglycerin because it leverages a new mechanism of action that could optimize existing therapies, making them more effective and possibly improving patient outcomes.

Research has shown that nitroglycerin can increase blood flow by widening blood vessels, making it a common treatment for heart problems. In this trial, participants with liver cancer, specifically hepatocellular carcinoma (HCC), will receive nitroglycerin injections to potentially enhance blood flow and improve the delivery of treatments directly to the tumor. Although direct evidence for liver cancer remains limited, the mechanism of nitroglycerin makes it worth exploring. Early studies in other conditions suggest that nitroglycerin can enhance the effectiveness of some treatments, indicating it might also aid in treating HCC when combined with methods like TACE, a treatment that cuts off the tumor's blood supply.